CA2389751A1 - Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes - Google Patents

Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes Download PDF

Info

Publication number
CA2389751A1
CA2389751A1 CA002389751A CA2389751A CA2389751A1 CA 2389751 A1 CA2389751 A1 CA 2389751A1 CA 002389751 A CA002389751 A CA 002389751A CA 2389751 A CA2389751 A CA 2389751A CA 2389751 A1 CA2389751 A1 CA 2389751A1
Authority
CA
Canada
Prior art keywords
nucleic acid
polypeptide
expression
cell population
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002389751A
Other languages
English (en)
Inventor
Fuad Mehraban
Mary Gerritsen
Luca Rastelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
CuraGen Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2389751A1 publication Critical patent/CA2389751A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

L'invention concerne des séquences d'acide nucléique et leurs polypeptides codés, exprimés de manière différentielle dans l'angiogénèse. L'invention concerne également des techniques de stimulation ou d'inhibition de l'angiogénèse chez les mammifères, notamment les humains. Elle concerne en outre des compositions pharmaceutiques à base de polypeptides, d'agonistes, ou d'antagonistes. Elle concerne, enfin, des techniques permettant de diagnostiquer et de traiter des troubles de l'angiogénèse notamment la cicatrisation de blessures et le cancer.
CA002389751A 1999-11-01 2000-11-01 Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes Abandoned CA2389751A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16269999P 1999-11-01 1999-11-01
US60/162,669 1999-11-01
US19680200P 2000-04-13 2000-04-13
US60/196,802 2000-04-13
US70335000A 2000-10-31 2000-10-31
US09/703,350 2000-10-31
PCT/US2000/030051 WO2001032926A2 (fr) 1999-11-01 2000-11-01 Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes

Publications (1)

Publication Number Publication Date
CA2389751A1 true CA2389751A1 (fr) 2001-05-10

Family

ID=27388787

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002389751A Abandoned CA2389751A1 (fr) 1999-11-01 2000-11-01 Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes

Country Status (4)

Country Link
JP (1) JP2003525595A (fr)
AU (2) AU784338B2 (fr)
CA (1) CA2389751A1 (fr)
WO (1) WO2001032926A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022625A1 (fr) * 2005-08-22 2007-03-01 Caprion Pharmaceuticals Inc. Procedes de reversion d'expression peptidique, et utilisations

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2798674B1 (fr) * 1999-09-21 2004-01-30 Mahmood Salman Al Procede d'identification de nouveaux genes impliques dans la regulation de l'angiogenese, etude de ces genes et leur utilisation a des fins therapeutiques
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
JP4486815B2 (ja) * 2001-09-27 2010-06-23 バイオノミックス リミテッド ヒト血管形成遺伝子に対するｄｎａ配列
AU2003286746A1 (en) * 2002-10-29 2004-05-25 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
US7407660B2 (en) 2003-04-16 2008-08-05 Genentech, Inc. Methods and compositions for selective modulation of vascularization
WO2005015227A1 (fr) * 2003-08-08 2005-02-17 Roche Diagnostics Gmbh Proteine t-plastine (plst) utilisee comme marqueur du cancer colorectal
WO2005015226A1 (fr) * 2003-08-08 2005-02-17 Roche Diagnostics Gmbh Utilisation de la plastine t de proteine (plst) comme marqueur du cancer colono-rectal
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
EP1721158A4 (fr) * 2004-01-13 2008-07-30 Rigel Pharmaceuticals Inc Modulateurs d'angiogenese
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
JP2006333770A (ja) * 2005-06-01 2006-12-14 Japan Science & Technology Agency 血管炎（ａｎｇｉｉｔｉｓ）患者の血液細胞特異的遺伝子群
WO2007015578A1 (fr) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. Procédé d’analyse de l’effet d’un inhibiteur de vascularisation
CN101316590B (zh) 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
RU2448708C3 (ru) * 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
JP2009537123A (ja) * 2006-05-18 2009-10-29 サノフィ−アベンティス Ａｄａｍｔｓ４遺伝子およびンパク質の多型の使用
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
WO2011162343A1 (fr) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent anticancéreux utilisant des composés ayant un effet inhibiteur de kinase en combinaison
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2994158A2 (fr) 2013-05-10 2016-03-16 Aarhus Universitet Régulateur de pappalysine
EP2997377B1 (fr) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de l' endometre vis-à-vis de composés lenvatinib
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
EP3624800A4 (fr) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. Traitement du carcinome hépatocellulaire
WO2024037387A1 (fr) * 2022-08-19 2024-02-22 Tianjin Yunjian Medical Technology Co., Ltd. Biomarqueurs sanguins et procédés de diagnostic de la maladie de kawasaki aiguë

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642353A1 (fr) * 1992-05-14 1995-03-15 Oncologix, Inc. Traitement du syndrome de permeabilite capillaire diffuse et des maladies induites par la collagenase par administration d'inhibiteurs de la metalloproteinase matricielle
CA2247246A1 (fr) * 1996-02-16 1997-08-21 Millennium Pharmaceuticals, Inc. Compositions et procedes de traitement et de diagnostic des maladies cardio-vasculaires
DE19701607A1 (de) * 1997-01-17 1998-07-23 Hoechst Ag Anitkörper, die an die Nidogen-Bindungsdomäne des Laminins binden, deren Herstellung und Verwendung
EP1070727A1 (fr) * 1999-03-01 2001-01-24 Aventis Pharma Deutschland GmbH Peptides à bas poids moléculaire comme inhibiteurs de l'interaction laminine/nidogene
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2387685A1 (fr) 1999-10-27 2001-05-03 Human Genome Sciences, Inc. Proteines et acides nucleiques de stanniocalcine et methodes afferentes
EP1268798B1 (fr) * 2000-03-29 2006-05-31 Beth Israel Deaconess Medical Center, Inc. Propriétés anti-angiogéniques de la proteine vascostatin et fragments et variants de celui-ci

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022625A1 (fr) * 2005-08-22 2007-03-01 Caprion Pharmaceuticals Inc. Procedes de reversion d'expression peptidique, et utilisations

Also Published As

Publication number Publication date
AU2006202570A1 (en) 2006-07-06
AU784338B2 (en) 2006-03-16
WO2001032926A3 (fr) 2002-12-05
AU1449301A (en) 2001-05-14
WO2001032926A2 (fr) 2001-05-10
JP2003525595A (ja) 2003-09-02

Similar Documents

Publication Publication Date Title
AU784338B2 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
US20080241835A1 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
EP1294876B1 (fr) Acides nucleiques eg-vegf et polypeptides et leurs procedes d'utilisation
AU768694B2 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2000053753A2 (fr) Activation ou inhibition de l'angiogenese et de la cardiovascularisation
JP2012246296A (ja) 血管形成及び心血管疾患の調節に使用する肝細胞成長因子の新規インヒビター
JP2003531811A5 (fr)
JP2009019032A (ja) 血管形成及び心臓血管新生の促進又は阻害
JP2002543784A (ja) 新規なチンパンジーエリスロポエチン（ｃｈｅｐｏ）ポリペプチドおよびこれをコードする核酸
JP2003511028A (ja) 新規ポリペプチド、その核酸および新脈管形成および血管新生におけるその使用のための方法
WO1999014234A2 (fr) Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation
WO2001040464A1 (fr) Kinase 3 associee au recepteur de l'interleukine 1 (irak3) et son utilisation pour stimuler ou inhiber l'angiogenese et la cardiovascularisation
CA2341767A1 (fr) Promotion ou inhibition d'angiogenese et de cardiovascularisation
EP2042597B1 (fr) Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
EP1287161A2 (fr) Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes
EP1734051A2 (fr) Composition et procédés de diagnostic de tumeurs
NZ532803A (en) Promotion or inhibition of angiogenesis and cardiovascularization
HK1128730A1 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
HK1128730B (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
ZA200105990B (en) Promotion or inhibition of angiogenesis and cardiovascularization.
NZ540754A (en) Promotion or inhibition of angiogenesis and cardiovascularization

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead